Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

istrative expenses is primarily due to cost savings related to recent restructurings.

The Company's balance sheet on September 30, 2008 reflected total assets of $207.7 million, including cash and investments of $118.2 million compared with balances at December 31, 2007 of $276.7 million and $179.4 million, respectively. The Company expects to end 2008 with approximately $100 million in cash and investments.

"We are pleased with the progress of our GnRH program, especially the recent positive results of our 603 study where once a day elagolix showed profound efficacy with minimal impact on bone mineral density. We are also nearing completion of the final preclinical studies of urocortin 2 to allow for long-term Phase II clinical studies and our scientists have just recently identified a clinical candidate from our VMAT2 development program for movement disorders," said Kevin Gorman, Chief Executive Officer and President of Neurocrine Biosciences. "While we are making great strides in advancing our pipeline, we continue to prioritize expenditures and diligently manage our cash burn."

R & D Pipeline Update

Neurocrine's clinical development group and corporate partners have five programs in clinical development. Neurocrine scientists continue to supply Neurocrine's pipeline to meet the Company-wide goal of bringing one new compound into development each year.

Elagolix for Endometriosis

The Company recently announced the positive safety and efficacy results from the completed 6-month treatment phase of its Phase IIb clinical trial (PETAL Study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix.

The primary endpoint, percent change from baseline in mean bone mineral density (BMD) demonstrated elagolix did not induce significant bone loss over the six month treatment period. Additionally, elagolix also met the secondary endpoints of improvement in endometrios
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
(Date:10/19/2014)... The Latin American hardware encryption display market ... with analysis and forecast of revenue. This market was ... to reach $2,366.8 million by 2018, at a CAGR ... the TOC of the Latin American hardware encryption market ... provided. It also provides a glimpse of the segmentation ...
(Date:10/19/2014)... The Asia-Pacific Speech Analytics market report defines and ... and forecast of revenue. This market is estimated to ... by 2019, at a Compound Annual Growth Rate (CAGR) ... the TOC of the Asia-Pacific Speech Analytics market report ... It also provides a glimpse of the segmentation in ...
(Date:10/18/2014)... The “Human Insulin Market- by Product Type, ... Human Insulin (Rapid Acting, Long Acting, Premixed)], by ... - Forecast to 2018” provides a detailed overview ... market trends, and strategies impacting the global human ... of the revenue and share analysis. , The ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
... Informex , the leading meeting place for buyers ... the Global Pharma Sourcing Conference to be held December ... Philadelphia, Pennsylvania. The two day program will be jointly ... address key issues that global chemical and pharmaceutical industry ...
... Corp. (IDC), a privately held biotechnology company developing ... and allergy, announced today that it has entered ... investigate the use of IDC,s Glucopyranosyl Lipid Adjuvant ... in the field of allergy. (Logo: ...
... Inc. (Nasdaq: SGMO ) today reported third quarter ... third quarter ended September 30, 2011, Sangamo reported a consolidated ... to a net loss of $8.7 million, or $0.19 per ... 30, 2011, the Company had cash, cash equivalents and marketable ...
Cached Biology Technology:Informex Introduces a Thorough Global Pharma Perspectives Conference 2Sangamo BioSciences Reports Third Quarter 2011 Financial Results 2Sangamo BioSciences Reports Third Quarter 2011 Financial Results 3Sangamo BioSciences Reports Third Quarter 2011 Financial Results 4Sangamo BioSciences Reports Third Quarter 2011 Financial Results 5Sangamo BioSciences Reports Third Quarter 2011 Financial Results 6
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... Researchers from the University of Copenhagen have shown for ... the lungs of Cystic fibrosis patients, giving them the ... growth in chronic infections. , The study also discovered ... fibrosis (CF) patients was halted or slowed down by ... consumed all the oxygen and helped "suffocate" the bacteria, ...
(Date:10/16/2014)... Oregon and Washington land managers have a new synthesis ... eastside moist mixed-conifer (MMC) forests in the two states. ... Forests in Eastern Oregon and Washington: A Synthesis of ... Management, a general technical report published by the U.S. ... response to a request from managers for a synthesis ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... at the Smithsonian and partnering organizations have discovered a remarkably ... the Republic of Palau. This fish exhibits many primitive anatomical ... 800 species of living eels, resulting in its classification as ... The team,s research is published online in the Proceedings ...
... Sons of male mice exposed to prenatal stress are ... in the August 17 issue of The Journal of ... lead to individual differences in stress response that may be ... of Pennsylvania, and colleagues previously found that male mice were ...
... and Switzerland have investigated the remarkable distance that microorganisms ... about their potential to colonise new lands and also ... John Moores University (LJMU), Swiss Federal Institute for Forest, ... Fdrale de Lausanne (EPFL) the University of Neuchtel published ...
Cached Biology News:Scientists discover the most primitive living eel 2Effects of prenatal stress passed across generations in mice 2Life on the wind: Study reveals how microbes travel the Earth 2
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
...
... serial preparation of four ... cytosol/particulate/cytoskeleton/nuclear fractions from one ... can directly be used ... as 2-D gel/Western blot/gel-shift/translocation/enzyme ...
Biology Products: